<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431350</url>
  </required_header>
  <id_info>
    <org_study_id>CR108406</org_study_id>
    <secondary_id>64091742PCR2002</secondary_id>
    <secondary_id>2017-003552-23</secondary_id>
    <nct_id>NCT03431350</nct_id>
  </id_info>
  <brief_title>A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <acronym>QUEST</acronym>
  <official_title>A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to
      evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1
      and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate
      (AA) in combination (Combination 3) in participants with metastatic castration-resistant
      prostate cancer (mCRPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter study will evaluate safety and efficacy of niraparib in combination with
      other anti-cancer agents. Combination 1 will combine niraparib with the anti-programmed cell
      death protein (PD)-1 monoclonal antibody cetrelimab, in participants with mCRPC. Combination
      1 has 2 parts: in Part 1 (dose selection), participants will be enrolled to establish RP2D
      doses of niraparib and cetrelimab; and Part 2 (dose expansion) will evaluate the combination
      therapy in an expanded number of participants into 2 cohorts (biomarker positive or biomarker
      negative). Combination 2 is closed to enrollment. Combination 3 will evaluate the relative
      bioavailability (BA) of niraparib and AA in combination. In pharmacokinetics (PK) assessment
      phase niraparib will be administered in combination with AA and in extension phase niraparib
      plus AA will be administered in combination with prednisone. Combinations 1 and 2 will have 4
      phases: A Pre-screening Phase, a Screening Phase, a Treatment Phase, and a Follow-up Phase;
      Combination 3 has 3 phases: A Screening Phase, A PK Assessment Phase, and an Extension Phase.
      Study evaluations will include efficacy, PK, PK/pharmacodynamics, biomarkers, safety and
      tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Combination 1: Incidence of Specified Toxicities</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Incidence defined as number of participants with specified toxicities will be reported. The dose will be considered intolerable if a participant developed Grade greater than or equal to (&gt;=) 3 non-hematological toxicity (with exceptions including anorexia, fever, constipation, fatigue that improves to Grade less than or equal to (&lt;=) 2 in &lt;=7 days, vomiting and diarrhea that resolves in &lt;=3 days with best supportive care), treatment-related Grade 4 thrombocytopenia or Grade &gt;= 3 thrombocytopenia, treatment-related Grade 4 neutropenia &gt;= 7 days, or Grade 3 or 4 neutropenia, treatment-related serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Combination 1: Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Objective response rate is defined as the percentage of participants who achieve complete response (CR) or partial response (PR), as assessed by response evaluation criteria in solid tumors (RECIST) 1.1 criteria with no evidence of bone progression according to prostate cancer working group 3 (PCWG3) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Combinations 1: Incidence of Adverse Events (AEs)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Incidence defined as number of participants with AEs will be reported. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Combinations 1: Severity of Adverse Events</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Any AE not listed in the NCI-CTCAE will be graded according to the investigator's clinical judgment using the standard grades.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination 3: Maximum Observed Analyte Plasma Concentration (Cmax) of Niraparib and AA After a Single Dose</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination 3: Maximum Observed Analyte Plasma Concentration for Niraparib Normalized by the Dose (Cmax/dose) of Niraparib and AA After a Single Dose</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>Cmax/dose is defined as maximum observed analyte plasma concentration for niraparib normalized by the dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination 3: Area Under the Plasma Concentration-Time Curve from Time Zero to 168 Hours (AUC [0-168]) of Niraparib and AA After a Single Dose</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>AUC (0-168) is defined as area under plasma concentration-time curve from time 0 to time 168 hours post dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination 3: Area Under the Plasma Concentration-Time Curve for Niraparib from Time Zero to 168 Hours (AUC [0-168]/dose) of Niraparib and AA After a Single Dose</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>AUC (0-168)/dose is defined as area under plasma concentration-time curve for niraparib from time 0 to time 168 hours post dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2 (Combination 1): Plasma Concentrations of Niraparib and Cetrelimab</measure>
    <time_frame>Cycle 1 up to 12 (each cycle is of 28 days)</time_frame>
    <description>Plasma concentrations of niraparib and cetrelimab will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2 (Combination 1): Number of participants with Anti-Drug Antibodies</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Number of participants with Anti-Drug Antibodies will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 1: Number of Participants with Circulating Tumor Cell (CTC) Response</measure>
    <time_frame>From screening up to end of treatment (30 days of last dose) (approximately up to 24 months)</time_frame>
    <description>CTC response is defined as CTC=0 per 7.5 milliliter (mL) of blood at 8 weeks for participants who have CTC &gt;= 1 at baseline or CTC&lt;5 per 7.5 mL with CTC &gt;=5 at baseline, confirmed by a second consecutive value obtained 4 or more weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 1: Composite Response Rate (RR)</measure>
    <time_frame>Screening, Cycle 1 (each cycle of 28 days) Day 1 (every 8 weeks for the first 6 months and then every 12 weeks thereafter) until follow-up phase (for 3 months) (approximately up to 24 months)</time_frame>
    <description>Composite RR is defined as percentage of participants who have 1 of the following by PCWG3: Objective response (confirmed per RECIST 1.1), or CTC response: defined as CTC=0 per 7.5 mL of blood at 8 weeks for participants who have CTC &gt;=1 at baseline or CTC &lt;5 baseline per 7.5 mL with CTC&gt;5 at baseline, confirmed by a second consecutive value obtained 4 or more weeks later, or PSA decline of &gt;= 50%, measured twice 3 to 4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 1: Duration of Objective Response</measure>
    <time_frame>Screening, Cycle 1 (each cycle of 28 days) Day 1 (every 8 weeks for the first 6 months and then every 12 weeks thereafter) until follow-up phase (approximately up to 24 months)</time_frame>
    <description>Duration of objective response is defined as time from complete response (CR) or partial response (PR) to radiographic progression of disease (PD), unequivocal clinical progression, or death, whichever occurs first. CR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 % decrease in sum of the diameters of the target lesions taking as reference the baseline sum diameters. PD is defined as a 20% increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 mm in the sum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 1: Overall Survival (OS)</measure>
    <time_frame>Up to follow-up (approximately up to 24 months)</time_frame>
    <description>OS is defined as time from start of treatment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination 3: Number of Participants with Adverse Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of participants with adverse events will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination 3: Number of Participants with Abnormal Clinical Laboratory Findings</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of participants with abnormal clinical laboratory findings (hematology and serum chemistry) will be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <arm_group>
    <arm_group_label>Combination 1:Dose Selection: Niraparib + cetrelimab(Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination 1:Dose Expansion: Niraparib + cetrelimab(Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination 3: Niraparib + AA + prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to one of the three cohorts to receive niraparib plus AA and prednisone as oral tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib 200 mg</intervention_name>
    <description>Participants will receive niraparib 200 mg orally.</description>
    <arm_group_label>Combination 1:Dose Expansion: Niraparib + cetrelimab(Part 2)</arm_group_label>
    <arm_group_label>Combination 1:Dose Selection: Niraparib + cetrelimab(Part 1)</arm_group_label>
    <arm_group_label>Combination 3: Niraparib + AA + prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrelimab 240 mg</intervention_name>
    <description>Participants will receive cetrelimab 240 mg IV every 2 weeks.</description>
    <arm_group_label>Combination 1:Dose Selection: Niraparib + cetrelimab(Part 1)</arm_group_label>
    <other_name>JNJ-63723283</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrelimab 480 mg</intervention_name>
    <description>Participants will receive cetrelimab 480 mg IV every 4 weeks.</description>
    <arm_group_label>Combination 1:Dose Expansion: Niraparib + cetrelimab(Part 2)</arm_group_label>
    <arm_group_label>Combination 1:Dose Selection: Niraparib + cetrelimab(Part 1)</arm_group_label>
    <other_name>JNJ-63723283</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate 1000 mg</intervention_name>
    <description>Participants will receive oral tablets comprising 1000 mg AA.</description>
    <arm_group_label>Combination 3: Niraparib + AA + prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone 5 mg</intervention_name>
    <description>Participants will receive prednisone 5 mg tablets orally.</description>
    <arm_group_label>Combination 3: Niraparib + AA + prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Combinations 1 and 2:

          -  Participants willing to undergo all protocol-specified biopsies

          -  Diagnosis of prostate adenocarcinoma as confirmed by the investigator

        Inclusion Criteria for Combination 1A:

          -  Must have determination of biomarker (BM) positive by the sponsor's blood or tissue
             assay, or a previous local test result (from a Clinical Laboratory Improvement
             Amendments [CLIA]-certified or equivalent laboratory) and reviewed by the sponsor to
             confirm eligibility

          -  Participants must have measurable disease as defined by response evaluation criteria
             in solid tumors (RECIST) 1.1 (soft tissue lesion of greater than or equal to (&gt;=) 10
             millimeter (mm) in the long axis or extrapelvic lymph node of &gt;=15 mm in the short
             axis)

          -  Must have previously received at least 1, but no more than 2, lines of novel androgen
             receptor (AR)-targeted therapy (that is, abiraterone acetate with prednisone,
             enzalutamide) for metastatic castration-resistant prostate cancer (mCRPC).
             Participants must have had at least 4 weeks of AR-targeted therapy

        Inclusion Criteria for Combination 1B:

        - Combination 1B is closed to enrollment

        Inclusion Criteria for Combination 2:

        - Combination 2 is closed to enrollment

        Inclusion Criteria for Combination 3:

        - Diagnosed with mCRPC, who in the opinion of the investigator may benefit from treatment
        in Combination 3 of this study

        Exclusion Criteria:

          -  History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia
             (AML)

          -  Active malignancies (that is, progressing or requiring treatment change in the last 24
             months) other than the disease being treated under study. The only allowed exceptions
             are: non-muscle invasive bladder cancer; skin cancer (non-melanoma or melanoma);
             breast cancer; malignancy that is considered cured with minimal risk of recurrence

          -  Active infection requiring systemic therapy

          -  Allergies, hypersensitivity, or intolerance to niraparib or the corresponding
             excipients

        Combination 1:

          -  Prior treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP)
             inhibitor

          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody

          -  Active autoimmune disease

        Combination 3:

          -  Symptomatic brain metastases

          -  Prior disease progression during combination treatment with AA and PARPi. Prior
             discontinuation of treatment with AA or PARPi due to AA- or PARPi-related toxicity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urology Centers Of Alabama</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona, P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Division Of Hematology/oncology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>First Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Oregon Urology Institute</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of SE PA</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MUSC-Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia, PLCC</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>5379200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Az Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Alberta Institute of Urology / Prostate Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Health Network (UHN) Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Regional du Cancer de Montpellier Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hopitalier Inter-Communal De Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>HIA Begin</name>
      <address>
        <city>Saint Mande</city>
        <zip>94163</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Asaf Harofe Medical Center</name>
      <address>
        <city>Beer Yaakov</city>
        <zip>60930</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soroka Hospital</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>85101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda USL Toscana Sud Est -Ospedale di Grosseto</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi di Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera ''Vito Fazzi''</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Ospedale Provinciale di Macerata</name>
      <address>
        <city>Macerata</city>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS-Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hosp. de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Fund. Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Hm Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen de La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Trust Sutton</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108406</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

